TPG, Permira emerge as frontrunners in Rs 11,000 crore Cloudnine sale

TPG Capital and Permira are leading contenders for a significant minority stake in Cloudnine. The deal is expected to value India's largest maternity and pediatric hospital chain at approximately ₹11,000 crore. Binding bids are anticipated by mid-August after due diligence is complete. This transaction will facilitate True North's full exit after over a decade of investment. Cloudnine posted ₹2,000 crore revenue and ₹300 crore Ebitda in FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1wR8BM2
via IFTTT

Read More

Lupin launches generic Sugammadex injection in US

Lupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Administration for its abbreviated new drug application. The company's injection is claimed to be bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade in adult and pediatric surgical patients. The launch occurred on Friday, as per a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BKHaYWf
via IFTTT

Read More

As we look to the next decade, I hope in the future we can further grow in generics as we transition into drug innovation: Aman Mehta, MD, Torrent Pharmaceuticals

Torrent Pharma aims to become a top three Indian drug maker. The company is transitioning from generics to drug innovation for growth. Aman Mehta leads the firm with an ambitious future vision. He spearheaded a significant acquisition and focuses on weightloss drugs. Mehta emphasizes making the right strategic decisions for success.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aa2ZNnG
via IFTTT

Read More

ChrysCapital acquires controlling 70.68% stake in Novartis' India listed unit in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6yfHqpD
via IFTTT

Read More

ChrysCapital acquires controlling 70.68% stake in Novartis India in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xmdxj2f
via IFTTT

Read More

FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

The FSSAI has suspended Dior Pharmaceuticals' license due to serious violations. The nutraceutical factory operated with severely deficient good manufacturing practices. These deficiencies posed a significant risk to public health and safety. The company failed to ensure product safety, quality, and traceability. All operations must cease until compliance is fully established.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SpORKHG
via IFTTT

Read More

Gland Pharma gets USFDA nod for generic sugammadex injection

Gland Pharma secured USFDA approval for its sugammadex injection generic version. This drug reverses muscle relaxant effects used during surgical procedures. The approval covers two specific strengths of the single-dose vial product. This new generic is bioequivalent to Merck's BRIDION injection. The product had significant US sales in the past year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NQSndia
via IFTTT

Read More

Biocon gets Health Canada nod for Yesintek autoinjector pen

Biocon received Health Canada approval for its Yesintek autoinjector. This new format offers patients a convenient treatment option for psoriasis. The autoinjector is also indicated for psoriatic arthritis and Crohn's disease. This approval strengthens Biocon's immunology product portfolio in Canada. The company aims to increase patient access to affordable medicines globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/npFjlZO
via IFTTT

Read More

BDR Pharmaceuticals eyes controlling stake in Acme Formulation

PAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder and managing director Viral Shah retained a significant minority stake after the transaction and continued as managing director and CEO. PAG owns about 62% of the company, while Shah holds around 31%, with the balance is owned by other investors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JmlhNyz
via IFTTT

Read More

Andhra Pradesh teams up with AstraZeneca for next-gen cancer care model

Andhra Pradesh signed an MoU with AstraZeneca for an integrated precision oncology ecosystem. This initiative will integrate artificial intelligence and advanced genomics for cancer care. The collaboration aims to transform patient journeys from screening to follow-up. AstraZeneca will deploy AI-powered solutions for early lung cancer detection. An Integrated Genomic Solutions Centre will expand access to advanced cancer diagnostics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/icoxMLN
via IFTTT

Read More

Alembic Pharma gets USFDA approval for generic chronic constipation treatment tablets

Alembic Pharmaceuticals announced USFDA approval for its generic prucalopride tablets. The company received final approval for strengths of one and two milligrams. These tablets are indicated for treating chronic idiopathic constipation in adults. The approved drug is therapeutically equivalent to Takeda's Motegrity tablets. This market segment has an estimated size of one hundred million dollars.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wv8WLxY
via IFTTT

Read More

Sakar Healthcare posts Rs 10-crore profit in Q1

Sakar Healthcare announced a substantial net profit increase for the first quarter of 2026-27. The company's revenue from operations also saw a significant rise during the same period. Its oncology business remains a key strategic focus for the pharmaceutical manufacturer. Sakar Healthcare executed numerous oncology product contracts and has many discussions ongoing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZGICO6T
via IFTTT

Read More

Centre readies healthcare compliance overhaul to boost hospitals in tier-2, tier-3 cities

India plans major healthcare regulatory changes soon. These reforms aim to simplify licensing and reduce compliance burdens. The government will release a consultation paper within two months. This initiative seeks to encourage private investment in smaller cities. The goal is to improve healthcare access across the nation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CrMLy1Q
via IFTTT

Read More

PHC Mogla brings healthcare closer to Rajouri's remote villages

PHC Mogla now offers essential healthcare services locally. Residents previously traveled long distances for basic medical treatment. A portable X-ray machine aids emergency care for injured patients. Maternal healthcare has also seen significant local improvements. This facility has become a crucial lifeline for remote villagers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0d3FwBE
via IFTTT

Read More

US tariff proposal wake-up call for Indian pharma to diversify, innovate: Experts

US pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market reliance. There are warnings that ensuring patient access to affordable medications should remain paramount.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yst4R6k
via IFTTT

Read More

Sculpt, lift, glow: Face fitness is having a moment in India

Face fitness is emerging as a new category in India’s beauty and wellness market, blending facial massage, muscle stimulation and skincare into studio-led treatments. Premium brands and homegrown players are expanding as consumers seek non-invasive alternatives to aesthetic procedures, driven by growing interest in wellness, grooming and preventive beauty.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lzFpKvR
via IFTTT

Read More

Aster DM Quality Care to invest Rs 1,315 crore in Karnataka

Aster DM Quality Care will invest Rs 1,315 crore in Karnataka's healthcare infrastructure. This significant investment aims to strengthen the state's medical facilities and services. The company plans to develop new hospitals and expand existing ones in Bengaluru. These developments will enhance access to advanced tertiary and quaternary care. The commitment underscores Aster's long-term confidence in Karnataka's healthcare ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gX19DFN
via IFTTT

Read More

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company aims for significant revenue growth by 2030 through new drug launches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/deDbnmy
via IFTTT

Read More

FSSAI suspends Rehaan Healthcare licence over serious food safety violations

FSSAI has suspended Rehaan Healthcare’s licence after inspections revealed serious violations at its health supplements and nutraceutical manufacturing facility. The regulator found extremely unhygienic conditions, poor infrastructure, pest infestation, inadequate storage, and major food safety lapses, resulting in a very low compliance score of 12%. The company has been ordered to halt production until all deficiencies are rectified and verified by the competent authority, failing which legal action may follow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u5PjhQJ
via IFTTT

Read More

Jackson Labs seeks restoration of its licence

The cancellation issued by the Punjab government followed reports that five women in Kota, Rajasthan, died after allegedly being administered an Oxytocin injection that upon testing found contained no active ingredient.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T9z30Rj
via IFTTT

Read More

India contributes one-third of global oral cancer burden; early detection key to survival, says oral cancer expert

India contends with a pressing oral cancer crisis, with thousands of new diagnoses and deaths emerging annually. The predominant factor behind this disease is the consumption of tobacco in diverse forms. Early detection via screening plays a critical role in managing and treating oral cancers successfully. It’s vital to monitor potentially malignant disorders closely and seek rapid medical assistance for ongoing oral health issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8OHqfZa
via IFTTT

Read More

Trump's 200% generic drug tariff threat puts $9.7 billion Indian pharma exports at risk; industry says reshoring not practical

US President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export significant generic medicines to the United States market. The proposed tariffs are set to begin in 2028, offering a two-year window. This lead time allows Indian firms to explore alternative export markets and adapt. American patients and insurers will likely face increased healthcare costs after tariffs are imposed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WvB3al9
via IFTTT

Read More

Dr Reddy’s aims to resume semaglutide supply by November after API fix

Dr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and plans corrective measures by September. Financial results were impacted by a provision linked to the semaglutide active pharmaceutical ingredient. Despite disruptions, Dr Reddy's maintains its growth and profitability guidance for fiscal year 2027. The drugmaker anticipates supplying millions of semaglutide units this fiscal year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xl093uB
via IFTTT

Read More

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After this period, tariffs will escalate significantly, impacting export economics. Several Indian firms already have US manufacturing operations for flexibility. The next two years will shape how India serves its largest overseas pharmaceutical market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PsQ6hON
via IFTTT

Read More

Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%

For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the immediate impact on exports is likely to be limited, the proposed escalation to 100% and eventually 200% tariffs could significantly alter the economics of supplying generic medicines to the US if manufacturers do not establish a stronger local production footprint.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KYmzZXp
via IFTTT

Read More

ICMR licenses cancer, vaccine technologies to Emcure, Biological E

The Indian Council of Medical Research has licensed three new biomedical technologies. These innovations aim to advance cancer treatment and infectious disease protection. One drug candidate targets precancerous cervical cells, offering a safer treatment option. Two vaccine candidates will combat major bacterial gut infections. This initiative promotes government research into practical healthcare products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gzI0XQD
via IFTTT

Read More

Glenmark sees innovative products driving 70% revenue in 5-6 years: CMD Glenn Saldanha

Glenmark anticipates innovative products will drive nearly seventy percent of its revenue. This strategic shift moves the company away from its traditional generics-led model. The company is developing next-generation products targeting oncology and other complex diseases. Glenmark aims to become a global powerhouse in oncology within ten years. Artificial intelligence will significantly accelerate drug discovery and development processes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jktyj1a
via IFTTT

Read More

Glenmark gets USFDA nod for expanded use of RYALTRIS nasal spray

Glenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve years. The nasal spray treats symptoms of seasonal allergic rhinitis effectively. RYALTRIS combines antihistamine and corticosteroid in one formulation. This marks a significant step in expanding access to the treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yL6MSw9
via IFTTT

Read More

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

India's drug regulator has approved Takeda's Qdenga dengue vaccine, the first of its kind. This vaccine is expected to become available in India during the first half of 2027. Qdenga offers protection against all four dengue virus serotypes for individuals aged four to sixty. The vaccine demonstrated significant efficacy in late-stage trials, reducing cases and hospitalisations. Takeda is also partnering with Biological E to boost global manufacturing capacity for Qdenga.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uXcade9
via IFTTT

Read More

Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment

Emcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treating metabolic dysfunction-associated steatohepatitis in adults. Poviztra contains innovator semaglutide manufactured in Europe by Novo Nordisk. The approval expands access to treatment for this progressive liver disease. This marks a significant milestone for patients with this serious condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/go3BxmL
via IFTTT

Read More

Takeda Biopharmaceuticals gets DCGI nod for dengue vaccine QDENGA

Takeda Biopharmaceuticals India has received market authorization for its dengue vaccine QDENGA. This vaccine is now approved for individuals aged four to sixty years old. QDENGA offers protection against all four dengue virus serotypes without prior testing. The vaccine has been approved in forty-three countries since its launch. India accounts for a significant portion of the global dengue burden.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eYgG18d
via IFTTT

Read More

Alcon to step up India investments; focus on innovation, training, says Senior Vice Prez Rajkumar Narayanan

Alcon is significantly increasing its investments in India's eye care market. The company sees India as a crucial emerging growth market for its future. Rising eye disorders among younger Indians are a key driver for Alcon's expansion. Alcon plans to enhance innovation and surgeon training programs across the nation. Future manufacturing in India is also being actively evaluated by the company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Amds2LF
via IFTTT

Read More

Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bn

Alembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug, which is a generic equivalent of Lynparza. Alembic will distribute the product while NATCO Pharma will manufacture the tablets. The product addresses a significant market opportunity, estimated at USD 1.4 billion. Commercial launch depends on ongoing litigation, marking a regulatory milestone.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4tEAoYG
via IFTTT

Read More

Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killer

India's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disease. The approval follows a committee recommendation for adults with moderate to advanced liver fibrosis. Wegovy, containing semaglutide, was previously approved for chronic weight management. This marks a significant expansion for the blockbuster obesity drug in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pCcdEbT
via IFTTT

Read More

Screens are straining young eyes, and Alcon sees India's opportunity

Alcon is increasing investments in India, recognizing its significant emerging market potential. The company focuses on innovation and surgeon training to address rising eye care needs. India's large population and growing myopia present substantial future growth opportunities. Alcon aims to enable advanced cataract care for millions by the year 2030. The global eye care leader is also evaluating future manufacturing possibilities within India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r3T1AC4
via IFTTT

Read More

Poly Medicure bets on new facilities, products to double international business: MD

The company's international business contributed ₹1,280.2 crore in FY26, accounting for nearly 68% of the company's total revenue of ₹1,875.3 crore. It expects the next phase of growth to be supported by two upcoming manufacturing facilities, a pipeline of more than 50 products, and a sharper focus on direct-market operations across key overseas geographies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VupHFhy
via IFTTT

Read More

Pharma exports to UK may rise up to 10% in FY27 as CETA takes effect

India's pharmaceutical exports to the UK are set to witness substantial growth thanks to the recently negotiated Comprehensive Economic and Trade Agreement. This groundbreaking agreement removes almost all tariffs on Indian drug products, enhancing the competitiveness of Indian generics and finished formulations. Preliminary data indicates promising trends in exports for this fiscal year, solidifying the UK's importance as a critical European market for India's pharmaceutical sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BSWdxhj
via IFTTT

Read More

India-UK FTA projected to boost Indian pharma exports by over 8% to $981 million in FY27: Pharmexcil

Indian pharmaceutical exports to the United Kingdom are projected to grow significantly. The India-UK Comprehensive Economic and Trade Agreement will eliminate tariffs on most products. This pact is expected to enhance the competitiveness of Indian generic medicines in the British market. The agreement also aims to secure supply chains and improve access to affordable medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sOz9NkP
via IFTTT

Read More

NITI Aayog roadmap targets USD 691 bn bioeconomy by 2035; Jitendra Singh says India ready to lead biotech revolution

India's bioeconomy can reach USD 691 billion by 2035, creating millions of high-value jobs. The nation aims to become a top global biotechnology power, driving future growth. A roadmap proposes six National BioMissions and a significant growth fund for development. Talent development, including engineering biology courses, is deemed critical for this ecosystem. This expansion will address national goals like health and food security.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jUBDlbs
via IFTTT

Read More

Kota kidney damage victims seek euthanasia or treatment in plea to President

Five women demand euthanasia after suffering kidney damage post C-section surgeries. They allege negligence and substandard drugs caused their critical health condition. Families face financial distress as husbands provide constant care for the ailing women. Repeated appeals to officials have yielded no resolution for their urgent medical needs. The petition seeks immediate kidney transplants and compensation or permission for dignified euthanasia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5GPctyg
via IFTTT

Read More

Warburg Pincus buys Mumbai’s pharma company Integrace in Rs 1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bWKc1ym
via IFTTT

Read More

Jitendra Singh releases Rs 1,500 crore under third phase of Biomedical Research Career Programme

Union Minister Jitendra Singh released fifteen hundred crore rupees for the Biomedical Research Career Programme. This funding supports outstanding biomedical researchers and promotes collaborative research initiatives. The program, initiated in two thousand eight, has supported over five hundred researchers. It has also strengthened research across more than two hundred institutions nationwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JrUtK9b
via IFTTT

Read More

Warburg Pincus buys Mumbai’s pharma company Integrace in ₹1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xiPgYI4
via IFTTT

Read More

Sun Pharma gets SAHPRA approval for generic semaglutide injection in South Africa for type 2 diabetes

South Africa's regulator approved Sun Pharma's generic semaglutide injection for diabetes. This approval allows marketing to supplement diet and exercise for adults. The company plans to launch the product soon in injectable pens. South Africa is the second market after India for this approval. This reflects Sun Pharma's commitment to improving access to generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S7kuYoN
via IFTTT

Read More

OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars

OneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSource providing integrated manufacturing capabilities for biosimilars. The partnership aims to expand access to high-quality, affordable biologics for patients globally. Formycon AG CEO stated this strengthens their supply capabilities with a quality-focused partner. Both companies aim to broaden sustainable global access to life-changing biosimilar therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EtkJz94
via IFTTT

Read More

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving access. Previously, patients received intravenous infusions, typically at clinics, for initial treatment. This approval differentiates Leqembi from competitor Kisunla's infusion-only requirement. The drug targets amyloid beta plaques in the brains of Alzheimer's patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oj2OFg0
via IFTTT

Read More

Warburg, Bain, CVC among PE firms in talks to buy into Agappe Diagnostics

Several global private equity firms are exploring a significant stake purchase in Agappe Diagnostics. This potential deal involves both existing investor sales and new capital infusion. The transaction is expected to value the Kochi-based in-vitro diagnostics firm at over three thousand crore rupees. Agappe Diagnostics develops and manufactures diagnostic reagents and equipment for global markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GAwaOnq
via IFTTT

Read More

Emcure buys remaining 12.05% in Gennova to take full control

Emcure Pharma is acquiring the remaining stake in Gennova Biopharmaceuticals. This move simplifies ownership and sharpens strategic focus for the subsidiary. Gennova will now be led by Samit Mehta for its next growth phase. The company will continue leveraging its biomanufacturing platforms for new products. Gennova's former CEO Sanjay Singh has divested its mRNA business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VYAtfO9
via IFTTT

Read More

First vaccine for Bundibugyo Ebola hits human trials in Oxford study

Oxford's Ebola vaccine candidate has entered Phase 1 clinical trials for safety evaluation. The ChAdOx1 BDBV vaccine uses a platform similar to the Covid-19 vaccine. Serum Institute of India manufactured approximately 620,000 doses for potential future use. This initiative builds on a strategic partnership with CEPI and the University of Oxford. Late-stage trials will follow if Phase 1 results prove successful.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ykevW63
via IFTTT

Read More

Schedule H1 explained: Why did India tighten its prescription rules for high-alcohol medicines?

Schedule H1 Explained: High-alcohol oral medicines now require a doctor's prescription under Schedule H1. This stricter classification mandates detailed sales records for pharmacies. The government aims to prevent misuse and diversion of these potent preparations. Previously exempt alcohol-based tonics face new licensing and prescription rules. Patients will need valid prescriptions for these medicines moving forward.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y318qeg
via IFTTT

Read More

Pharma body renews push for data protection

Leading pharmaceutical companies seek Regulatory Data Protection to boost research investments. Public health groups and local makers oppose this, fearing extended monopolies and delayed generics. The Organization of Pharmaceutical Producers of India argues it benefits indigenous drug makers too. China has already implemented similar clauses, seeing significant research deal growth. India's regulatory alignment with global practices could attract discovery research investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RGLQobI
via IFTTT

Read More

Antibiotic resistance emerging as major threat to surgical care: Experts

Antimicrobial resistance now challenges routine surgical procedures and increases infection risks. Surgeons warn that losing effective antibiotics undermines decades of progress in safe surgery. Hospitals are adopting stricter antibiotic stewardship and infection prevention measures. Multidrug-resistant organisms pose a significant challenge to treating post-operative infections effectively. Preserving antibiotic effectiveness is a shared responsibility for future generations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1wU9h0H
via IFTTT

Read More

Maharashtra FDA bars sale of two Cadila drugs over branding concerns

Maharashtra FDA has seized Cadila Pharmaceuticals drug stock worth Rs 2.45 crore. The action was taken due to similar branding on different active ingredients. Officials barred sales of Aciloc 150 Plus and Aciloc 300 Plus medicines. This move aims to prevent medication errors and safeguard public health. Further investigation and legal action are currently underway.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JnbCdmg
via IFTTT

Read More

Medicines with over 12% alcohol can no longer be sold without prescription: Govt

In a new regulatory change, medications with alcohol content exceeding twelve percent will require a prescription from a doctor. This decision treats these products like standard prescription drugs, compelling manufacturers to obtain the necessary licenses. Furthermore, pharmacies are now tasked with rigorous record-keeping to mitigate potential abuse and ensure that genuine medical use is preserved under enhanced scrutiny.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KFcNM9Q
via IFTTT

Read More

Dr Reddy’s pauses weight loss drug on quality fears

Dr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the active pharmaceutical ingredient manufacturing scale-up. The company assures that already supplied market products remain safe for patient use. Torrent Pharmaceuticals and USV Ltd are recalling some semaglutide batches sourced from Dr Reddy's. Commercial supplies are expected to resume after the issue is resolved and validation is complete.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dwmf6Hl
via IFTTT

Read More

GA-Renova & CCA in race to buy American oncology: Siemens Healthineers looking to exit non-core business for Rs 1,500 crore

Two prominent players are in the running to purchase American Oncology Institute from Siemens Healthineers. One of the potential buyers is General Atlantic in collaboration with Renova Hospitals, while the other contender is Raj Mantena's Cancer Centers of America. Siemens Healthineers initially acquired this cancer network as part of a larger strategic agreement. The completion of the sale is anticipated by mid-August.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SNcbioP
via IFTTT

Read More

Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient concern. The firm is actively investigating to identify the source of the problem and is implementing corrective strategies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0z2tmvd
via IFTTT

Read More

Novo Nordisk readies once-a-week insulin shot for Indian market

Novo Nordisk is set to introduce Awiqli, an innovative once-weekly insulin, in India shortly. This remarkable treatment drastically cuts down the number of insulin injections from 365 annually to only 52. Awiqli could redefine the approach to diabetes management, offering promising cost savings compared to existing therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ChAb7oH
via IFTTT

Read More

Cultural sensitivity, communication key to strengthening India's medical tourism appeal: IIM experts

Experts highlight cultural sensitivity and communication's importance for international medical tourists. Effective expectation management and communication enhance patient experiences in Indian hospitals. India is a leading medical tourism destination due to advanced healthcare and affordable costs. Hospitals should invest in intercultural communication training for professionals. Bridging cultural gaps improves patient satisfaction and India's market competitiveness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OCSImb8
via IFTTT

Read More

Navi Mumbai Airport notified as port for import of drugs under Drugs Rules

Navi Mumbai Airport has been designated as a port for drug imports, a decision that boosts the pharmaceutical supply chain and simplifies trade activities. Following the amendment to Drugs Rules, 1945, the total number of notified ports has increased to 42. This initiative is aimed at facilitating efficient movement of pharmaceutical goods and enhancing regulatory oversight, showcasing the government's dedication to improving trade dynamics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AWFJEtN
via IFTTT

Read More

Regulator seeks views to curb similar sounding drug brands

The Central Drugs Standard Control Organisation in India is inviting public contributions concerning new regulations aimed at curbing the sale of various medications under similar brand names, which can mislead both patients and pharmacists about their contents. As part of this initiative, the drug regulator has released a notice for stakeholder observations, with a deadline for comments set for July 17 to ensure improved safety and trust among patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nTO3oJP
via IFTTT

Read More

India's wellness industry poised for growth amid focus on preventive healthcare, rising income: EBG Group chief

India's wellness market, valued at over $150 billion, is set for growth fueled by rising health consciousness and disposable incomes. EBG Group is launching Carlton Wellness India, an integrated ecosystem blending traditional Indian healing with modern hospitality. This platform will offer diverse wellness experiences, from city centers to retreats, emphasizing preventive care and holistic wellbeing for everyday life.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WPFLkpU
via IFTTT

Read More

Gene therapy firm Immuneel ties up with Arogya Finance to offer Rs 25 lakh zero-cost EMI for cancer treatment

Immuneel Therapeutics collaborates with Arogya Finance to unveil a zero-cost EMI scheme for advanced cancer treatments, providing support of up to Rs 25 lakh. This effort is a segment of Immuneel's Saksham Patient Access Program, letting eligible patients benefit from interest-free installments for as long as 12 months, thereby reducing financial pressures and facilitating prompt access to essential therapies for those in need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9GLTgKS
via IFTTT

Read More

Glenmark launches generic Olanzapine injection in US

Glenmark Pharmaceuticals has launched a generic version of Olanzapine injection in the United States, offering a treatment for schizophrenia and bipolar disorder. This move by its US arm, Glenmark Pharmaceuticals Inc., introduces a bioequivalent alternative to Zyprexa intramuscular injection. The company aims to expand its injectable offerings and bolster its presence in the institutional market, targeting a segment with significant annual sales.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cZKjp6i
via IFTTT

Read More

Death in a vial: Five cases lay bare many uncomfortable truths about Indian healthcare

Five young mothers in Kota died after childbirth, with suspicion falling on oxytocin injections. Investigations revealed the vials contained only water, not the active ingredient. The manufacturer, Jackson Laboratories, has had stop-production orders earlier as well. This incident has put focus on critical failures in drug regulation and raises serious concerns about patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iaItPh9
via IFTTT

Read More

Adani Group to set up 2,000-bed hospital in New Town: Bengal CM

West Bengal Chief Minister Suvendu Adhikari announced that the Adani Group will establish a 2,000-bed hospital in New Town. A significant portion, 1,000 beds, will be dedicated to providing free treatment for the underprivileged. The remaining beds will be utilized for commercial operations. This initiative was revealed during an interaction with civil society members, highlighting the government's recent efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MkG8EVN
via IFTTT

Read More

OnCare launches cancer treatment centre in Bengaluru

Bengaluru now has a new cancer treatment centre launched by OnCare, aiming to bring accessible, affordable, and patient-friendly oncology services to the region. Following success in Delhi-NCR, the facility offers comprehensive care including chemotherapy, immunotherapy, and supportive services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4oBSebW
via IFTTT

Read More

Fortis Healthcare inks pact with Dion Group for 300-bed hospital in Cuttack

Fortis Healthcare is set to manage and operate a new 300-bed multi-specialty hospital in Cuttack, Odisha, a project valued at Rs 600 crore. Developed by Dion Group, the facility aims to significantly enhance access to advanced tertiary care for residents of Cuttack, Bhubaneswar, and surrounding areas. This collaboration merges Fortis's extensive healthcare expertise with Dion's infrastructure development vision, promising quality medical services closer to home.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mTuJNxy
via IFTTT

Read More

Sun Pharma secures relief in 'Pantocid' trademark dispute

Delhi High Court has halted Ahmedabad-based Finecure Pharmaceuticals from producing and selling drugs with names similar to Sun Pharma's 'Pantocid'. The court permitted Finecure to sell existing stock of 'Pantopacid' within four months, provided an affidavit detailing the inventory is filed. This decision overturns a previous ruling that had refused to grant an injunction against Finecure, highlighting significant sales disparities between the two companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j2dpVz7
via IFTTT

Read More

Syngene International MD & CEO Peter Bains resigns

Bains has resigned from the position of MD & CEO with effect from the close of business hours on June 30, Syngene International said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YdApZaN
via IFTTT

Read More

Zydus Lifesciences ties up with Apollo Hospitals to offer Shield multi-cancer detection test

Zydus Lifesciences has partnered with Apollo Hospitals to introduce the Shield multi-cancer detection test in India, made possible through an agreement with Guardant Health. This innovative blood test can identify signals for multiple cancer types in individuals aged 45 and above. The collaboration aims to enhance early cancer detection and improve patient outcomes across the nation, making advanced screening more accessible.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7sBNd9h
via IFTTT

Read More

New rules simplify drug launches, reduce manufacturer liability for overcharging

New rules now allow drug manufacturers to launch similar medicines without prior price approval, streamlining market entry. Companies can seek varied prices for drug variants based on packaging and dosage, fostering flexibility. Overcharging liability is now limited to specific distributors if manufacturers prove compliance, easing burdens for many firms. Stricter record-keeping for seven years is also mandated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ciaZRXt
via IFTTT

Read More

Shantha Biologics to make injectable drug cartridges for Novo Nordisk

Shantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable medicines at its Hyderabad facility. This partnership highlights India's growing role in advanced pharmaceutical manufacturing, particularly for high-demand diabetes and obesity therapies. Shantha's FDA-approved, automated fill-finish lines will produce these critical components, underscoring the company's expanding capabilities in contract manufacturing for biologics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eqmNj5D
via IFTTT

Read More

Generics must not be imperiled over data protection: Satish Reddy, Chairman, Dr Reddy's Laboratories

Dr Reddy's chairman, Satish Reddy, has raised concerns about compromising India's competitive edge in generics for foreign investments. He stresses the importance of aligning capital with developmental needs and enhancing collaboration between academia and industry. Advocating for a national mission akin to China's, he highlights the necessity of structured government procurement to stimulate drug innovation and underscores AI's transformative role in drug discovery, contingent on adaptive regulatory systems.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zy56Brh
via IFTTT

Read More

Telangana bets big on drug discovery hub

Telangana is gearing up to elevate Hyderabad's pharmaceutical standing beyond manufacturing. The state is fostering an integrated ecosystem for drug discovery and development, bringing together industry, research, startups, and investors. This strategic move aims to position Telangana as a hub for next-generation therapies, leveraging its existing strength as a global vaccine production leader.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O9uben6
via IFTTT

Read More

Mankind Pharma partners Denovo Sciences for AI-led drug discovery

Mankind Pharma has partnered with Denovo Sciences to accelerate drug discovery using artificial intelligence. This collaboration aims to significantly cut down early research timelines, enhance the quality of potential drug candidates, and ensure only the most promising ones advance. By combining Mankind Pharma's R&D prowess with Denovo's AI platform, the companies expect to bring effective and accessible treatments to patients faster, marking a significant step in innovation-driven research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GtiF5H8
via IFTTT

Read More

mRNA vaccines protect against severe infectious diseases, review confirms

Billions of mRNA vaccine doses administered globally confirm their safety and effectiveness against infectious diseases, including severe COVID-19, across all age groups and health conditions. Researchers emphasize that serious side effects are rare, with benefits far outweighing risks. This technology, now proven, holds immense promise for future vaccines and personalized treatments, though equitable global access remains crucial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZiMdsJ0
via IFTTT

Read More

Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discovery

Mankind Pharma has joined forces with Denovo Sciences to revolutionize drug discovery using artificial intelligence. This strategic partnership aims to significantly shorten development timelines, improve the quality of potential drug candidates, and identify the most promising options. By integrating AI with human expertise, the companies are set to accelerate the delivery of effective and accessible new medicines to patients, marking a significant step forward in pharmaceutical innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oHUbqxj
via IFTTT

Read More